SCHEMBL24577850

SCHEMBL24577850

Cc1cc(C(=O)NCCCN2CCCC2(C)C)sc1NC(=O)c1cnn2cc(-c3cnn(C)c3)sc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRA P16234 3/20 0.47
▸ CHRM1 P11229 1/20 0.47
▸ HRH3 Q9Y5N1 1/20 0.47
▸ MARK3 P27448 5/20 0.32
▸ KDM4E B2RXH2 2/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ LMNA P02545 2/20 0.31
▸ POLB P06746 2/20 0.31
▸ HSD17B10 Q99714 2/20 0.31
▸ RAD52 P43351 2/20 0.31
▸ TP53 P04637 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ STAT1 P42224 1/20 0.31
▸ GFER P55789 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ FGFR1 P11362 1/20 0.30
▸ FGFR2 P21802 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24578408 0.96 PDGFRA (0.52) PDGFRACHRM1HRH3MARK3MAPK1
SCHEMBL24577027 0.88 PDGFRA (0.44) PDGFRACHRM1HRH3MARK3MAPK1
SCHEMBL24577616 0.88 PDGFRA (0.44) PDGFRACHRM1HRH3MARK3MAPK1
SCHEMBL24577101 0.88 PDGFRA (0.44) PDGFRACHRM1HRH3MARK3MAPK1
SCHEMBL24578932 0.88 PDGFRA (0.45) PDGFRACHRM1HRH3
SCHEMBL24577177 0.87 PDGFRA (0.46) PDGFRACHRM1HRH3KDM4EALDH1A1
SCHEMBL24577222 0.86 PDGFRA (0.48) PDGFRACHRM1HRH3
SCHEMBL29759932 0.86 PDGFRA (0.48) PDGFRACHRM1HRH3
SCHEMBL24577612 0.86 PDGFRA (0.45) PDGFRACHRM1HRH3KDM4EALDH1A1
SCHEMBL24578906 0.85 CHRM1 (0.39) PDGFRACHRM1HRH3MARK3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2024-04-04 — — US disclosed
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 — — EP disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS PDGFRA, PDGFRB, ABL1 PDGFRA 1/4885CHRM1 4399/4885HRH3 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback